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1. Introduction 
Inflammatory bowel disease (IBD) refers to a group of conditions characterised by 
inflammation in the intestinal tract. Crohn disease (CD) and ulcerative colitis (UC) account 
for the majority of these conditions. Since these disorders have both distinct and 
overlapping pathologic and clinical characteristics in this part both diseases are discussed 
together. 
Multiple studies have evaluated the epidemiology of IBD in various geographic regions. In 
North America, incidence rates range from 2.2 to 14.3 cases per 100,000 person-years for UC 
and 3.1 to 14.6 cases per 100,000 person-year for CD ([1]). Prevalence rates range from 37 to 
246 per 100,000 persons for UC and from 26 to 201 cases per 100,000 for CD. The incidence 
and prevalence of CD and UC appear to be lower in Asia, Japan, and South America ([2]). 
IBD can present at any age, although the peak incidence occurs between the ages of 15 and 
30 years. A second peak in the incidence of CD occurs between the ages of 50 to 80. There is 
no gender specificity ([3, 4]). 
While numerous environmental factors have been hypothesized to affect risk of a phenotype 
of IBD, only a few associations have been reproducible and implicated in the pathogenesis 
of IBD. These factors as smoking, appendectomy, infection, oral contraceptives, isotretinoin 
are more likely to contribute to disease in susceptible subjects ([2]). 
The strongest evidence for an environmental factor has been the association between 
cigarette smoking and IBD. Several studies have demonstrated a negative correlation 
between smoking and UC, but a positive correlation between smoking and CD recurrence 
([5, 6, 7, 8, 9, 10]). 
A variety of conditions arise outside of the gastrointestinal tract that are associated with 
IBD; these are termed extraintestinal manifestations of IBD which are very common: 
dermatological manifestations, erythema nodosum and pyoderma gangrenosum; ocular 
manifestations, uveitis and episcleritis; hepatobiliary manifestations, primary sclerosing 
cholangitis and autoimmune hepatitis; musculoskeletal manifestations, peripheral arthritis 
and axial arthropathy. In contrast, pulmonary involvement is rare ([11]). 
Involvement of the respiratory tract, although relatively rare, is increasingly recognized in 
patients with IBD since the original report in 1976 of six patients with unexplained chronic 
purulent sputum production ([12]). These abnormalities are generally related to the 
underlying bowel disease, although interstitial lung disease can also be induced by 
www.intechopen.com
 
Ulcerative Colitis – Epidemiology, Pathogenesis and Complications 
 
258 
administration of certain drugs, including sulfasalazine, 5-aminosalicylic acid, methotrexate, 
azathioprine and infliximab ([13, 14, 15, 16, 17]). 
2. Demographic considerations 
Respiratory complications have been more commonly described with ulcerative colitis than 
with Crohn's disease. In one study of 33 patients, for example, 27 had ulcerative colitis and 
six had Crohn's disease. The three patterns of presentation (airway disease, parenchymal 
disease, and serositis) had somewhat different characteristics in terms of sex preponderance 
and activity of the bowel disease ([12]). There was a female preponderance of almost 2:1 for 
all bronchopulmonary complications as a whole and 3 to 4:1 for bronchial complications. In 
contrast, serositis occurred with roughly equal frequency in men and women. 
Bronchopulmonary complications followed the onset of inflammatory bowel disease in 80 to 
85 percent of patients, preceded bowel disease in 10 to 15 percent, and developed 
concomitantly in 5 to 10 percent ([12]). 
Respiratory involvement in IBD is disclosed with some pathophysiological mechanisms: 
both the colonic and respiratory epithelia share embryonic origin from the primitive foregut, 
and both types of epithelial cells include goblet cells and submucosal glands; and the lungs 
and gastrointestinal tract contain submucosal lymphoid tissue and play crucial roles in host 
mucosal defense. The similarity in the mucosal immune system causes the same 
pathogenetic changes. The aberrations in both innate and acquired immunity that are 
involved in the pathogenesis of IBD are complex and still incompletely understood ( [11, 
17]). In this context it has been speculated that colonic surgery may promote the onset of 
respirtory, as suggested by case histories ([12]). 
The patterns of involvement in IBD are ([11, 17]): 
- Upper airway: glottic/subglottic stenosis, tracheal inflammation and stenosis; 
- Bronchi: chronic bronchitis, bronchiectasis, and chronic bronchial suppuration; 
- Small airways: bronchiolitis obliterans, bronchiolitis, and diffuse pan-bronchiolitis;  
- Lung parenchyma: bronchiolitis obliterans-organizing pneumonia, nonspecific 
interstitial pneumonia, granulomatous interstitial lung disease, desquamative 
interstitial pneumonitis, pulmonary infiltrates and eosinophilia, and sterile necrobiotic 
nodules; 
- Sarcoidosis, α1 antitrypsin deficiency; 
- Pulmonary vascular disease; Wegener’s granulomatosis, Churg-Strauss syndrome, 
microscopic polyangiitis, and pulmonary vasculitis, venous thromboembolism; and -
Serositis: pleural and pericardial manifestations. 
3. Respiratory symptoms 
The prevalence of respiratory symptoms in IBD patients without pulmonary pathology has 
been examined in a number of small studies. Among 44 randomly selected IBD patients, 
Douglas et al ([18]) found that 48% had unspecified respiratory symptoms. Songur et al 
([19]) found that 16 of 36 IBD patients (44%) in a gastroenterology clinic had symptoms of 
wheeze, cough, sputum production, or breathlessness. Finally, Ceyhan and others ([20]) 
found 15 of 30 consecutively surveyed IBD patients had symptoms of dyspnea, cough, 
sputum, or wheeze for > 1 month. These investigations, while limited in scope, suggest that 
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patients with IBD have pulmonary symptoms with greater frequency than the general 
population. 
4. Radiologic findings 
Chest radiography is often normal in patients with respiratory symptoms and IBD. 
Bronchiectasis is the classic pulmonary manifestation of IBD, and is noted in 66% of cases of 
IBD that involve the large airways ( Figure 1)([17]). 
 
 
Fig. 1. CT showing bronchiectasis and inflammatory nodules in a 72-year-old woman with 
UC ([17]) 
Mahadeva et al ([21]) have found bronchiectasis in 13 of 17 patients with IBD, in whom 
sputum production was present in 10. In contrast, bronchiectasis was identified in only two 
patients in the present study. In the study of Yilmaz et al, the most frequent finding on 
HRCT was peribronchial thickness. The most common respiratory association of IBD is 
inflammation of the airways. Biopsy shows either severe nonspecific chronic inflammation 
or non-caseating tuberculoid granulomas. They concluded that these appearances have been 
associated with those in the bowel, and it is possible that the gut and the lung are both 
affected because they share common antigens. This inflammation is perceived on HRCT as 
an increase in bronchial wall thickness or an increase in diameter of pulmonary artery 
branches. In these patients, bronchial dilatation is commonly present and results from 
traction by fibrous tissue on the bronchial walls and results in bronchiectasis. Consequently, 
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they suggested that peribronchial thickness might reflect inflammation, which usually 
responds well to steroids. They concluded that in this way, bronchiectasis can be prevented. 
And so this finding suggests a direct pathogenic link to IBD as well ([11]). 
5. Pulmonary function 
A number of investigations have focused on results of pulmonary function testing (PFT) 
among patients with IBD. Case-control studies designed to investigate the hypothesis that 
IBD is associated with abnormal pulmonary function have been limited by low numbers of 
patients and poor choice of control subjects. A number of reports have demonstrated a 
decrease in diffusion capacity of the lung for carbon monoxide (DLco). Two studies by 
Tzanakis et al ([22, 23]) have shown that DLco was significantly lower among IBD patients 
with active GI disease than those in remission. In the same study an increased prevalence of 
small airway dysfunction among IBD patients have shown. Marvisi et al ([24]) reported a 
similar finding in a smaller cohort with UC. This suggests that degree of GI inflammation 
may correlate with the severity of lung disease in these patients. 
Other reports have employed less conventional measures of airflow obstruction to identify 
subclinical pulmonary disease. Patients with active UC had increased airway obstruction 
compared with patients with inactive UC. Pasquis et al ([25]) found an increase in functional 
residual capacity among a small number of patients with CD. Two groups, Mansi and 
colleagues ([26]) and Louis et al ([27, 28]) have documented increased bronchial response to 
methacholine, a measure of airway hyperactivity, among patients with both UC and CD, but 
this was not confirmed in another study.  Ceyhan et al revealed that the prevalence of 
allergic symptoms, positive skin tests, and functional abnormalities was significantly higher 
in patients with IBD. ([20]). 
Nitric oxide (NO) is a mediator of inflammation in a number of pathological processes. It is 
elevated in exhaled air (eNO) from asthmatic patients compared with healthy volunteers, 
and also in aspirated colonic gas from patients with Crohn's disease. Koek et al studied 31 
patients with Crohn's disease and 24 with ulcerative colitis. The authors found that eNO 
was elevated in active IBD, and in addition, observed a negative correlation between 
spirometry values and disease activity in patients with Crohn's disease ([29]). Ozyilmaz et al 
evaluated the value of fractional concentration of exhaled NO (FeNO) level for the diagnosis 
of pulmonary involvement due to IBD and to investigate any correlation between FeNO 
level and disease activity. They concluded that an increased FeNO level may be used for 
identifying patients with IBD who need further pulmonary evaluation ([30]) . 
6. Patterns of involvement 
Upper airway: Glottic/subglottic stenosis, tracheal inflammation and stenosis; are 
associated with inflammation, friability, and pseudotumors in the trachea which results in 
airway narrowing. The primary symptoms are cough and hoarseness, although some 
patients develop upper airway obstruction with resulting stridor and severe dyspnea ([20]). 
In endoscopic examination glottic/subglottic oedema, inflammation can be seen. 
Airway inflammation: Chronic bronchitis, bronchiectasis, and chronic bronchial 
suppuration; inflammation of the trachea, bronchi, and bronchioles can occur in 
inflammatory bowel disease, with bronchial involvement being most common, accounting 
for 39% of all cases reviewed ([12, 31, 32, 33]). Patients with large airways disease may also 
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have coincident nonthoracic extraintestinal manifestations, including microangiopathic 
hemolytic anemia, pyoderma gangrenosum, primary sclerosing cholangitis, episcleritis, and 
peripheral and axial arthritis. Bronchial involvement may be manifested as unexplained 
chronic bronchitis or as bronchiectasis. Bronchiectasis is the classic pulmonary manifestation 
of IBD, noted in 66% of instances of IBD involving the large airways ([17]). Patients can be 
asymptomatic or present with cough and variable amounts of mucopurulent sputum 
production. Cultures of bronchial secretions are typically unrevealing, and the symptoms 
are generally not responsive to antibiotics. Chest radiographs are frequently normal or show 
nonspecific changes resulting from bronchial wall thickening or bronchiectasis. High 
resolution chest CT scanning is more sensitive than plain chest radiographs, often 
demonstrating findings of bronchial wall thickening, dilated airways with thickened walls, 
or branched opacities suggestive of mucoid impaction ([34, 35]). 
Interestingly, nine patients, mostly with UC, presented with or had a recrudescence of 
bronchiectasis within 1 year of colectomy. In one case, bronchiectasis presented within 
weeks of colectomy. This temporal link between colonic resection and onset or worsening of 
pulmonary disease has fueled speculation that colectomy may actually induce pulmonary 
disease in these patients ([12]). Alternatively, this phenomenon may be related to the 
discontinuation of immunosuppressive therapies after presumed surgical cure of the disease 
([17]). 
Small airway involvement: Bronchiolitis obliterans, bronchiolitis, and diffuse pan-
bronchiolitis; can cause cough, variable sputum production, wheezing, and airflow 
obstruction. Small airway involvement in IBD tends to present at a younger age and at an 
earlier point in the disease course than abnormalities of the large airways. In contrast to 
other airway manifestations, diseases of the small airways more commonly occur before 
symptomatic GI disease (29% of surveyed cases) ([17]). Pathologic findings include 
nonspecific inflammation, narrowing, and fibrosis of small airways; granulomatous 
bronchiolitis ( 58.8%) has also been reported ([15, 36]). Small airway involvement can cause 
abnormalities in pulmonary function in patients with normal chest radiographs. In one 
series of 82 patients with IBD and normal plain chest radiographs, 47 (57 percent) had 
abnormal findings on complete pulmonary function tests ([16]). Most of these patients had 
findings consistent with restrictive lung disease. High resolution chest CT can demonstrate 
mosaic perfusion or tree-in-bud ([12]). 
Pulmonary parenchymal disease: Bronchiolitis obliterans-organizing pneumonia(BOOP), 
nonspecific interstitial pneumonia, granulomatous interstitial lung disease, desquamative 
interstitial pneumonitis, pulmonary infiltrates and eosinophilia, and sterile necrobiotic nodules. 
Several patterns of lung parenchymal involvement have now been described in 
inflammatory bowel disease, with bronchiolitis obliterans with organizing pneumonia and 
interstitial lung disease being most common ([12, 13]). UC is the underlying form of IBD in 
the majority of reported cases of IBD-associated parenchymal lung disease. Age of onset 
varies, and there is a slight female predominance. One study of 85 patients with ulcerative 
colitis and 47 patients with Crohn's disease found that diffusing capacity was significantly 
lower during exacerbations of bowel disease than when gastrointestinal disease was 
quiescent ([22]). No pulmonary symptoms were associated with these transient physiologic 
derangements. These results have been confirmed in other reports, suggesting that 
pulmonary inflammation commonly accompanies inflammation of the bowel ([24]). 
BOOP presents in an acute or subacute fashion with variable combinations of fever, 
dyspnea, cough, and pleuritic chest pain ([12]). Chest radiographic findings range from 
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patchy focal opacities to diffuse infiltrates, while CT scanning often demonstrates the opacities 
to be pleural-based and sometimes associated with air bronchograms (Figure 2) ([21]). 
 
 
Fig. 2. High resolution computed tomography. On expiration, there is evidence of extensive 
air trapping in keeping with obliterative bronchiolitis ([21]) 
Sarcoidosis: IBD and sarcoidosis are usually considered to be distinct entities. However, the 
cumulative volume of case reports documenting coexistence of these two entities suggests a 
link between them. Fifty-three cases of IBD and concomitant sarcoidosis have been reported 
in the literature ([17]). The pathophysiologic basis of a relationship between IBD and 
sarcoidosis is unclear. Genetic susceptibility and derangements of cellular immunity play 
important roles in the development of both. Barr et al reported that human leukocyte 
antigen (HLA)-B8 and HLA-DR3 haplotypes were present in three of eight patients with UC 
and sarcoidosis, a higher proportion than expected ([37]). Papadopoulos et al reported a 
greater incidence of a variety of autoimmune diseases in patients with sarcoidosis, and 
suggested that HLA-linked genetic susceptibility (HLA-B8/DR3) predisposes sarcoidosis 
patients to a variety of autoimmune diseases ([38]). Finally, IBD and sarcoidosis share 
comparable dermatologic, ocular, and joint manifestations, further suggesting a pathogenic 
link. Nontuberculous Mycobacterium species have been postulated as an infectious cause of, 
and have been detected in tissues from patients with, both IBD and sarcoid ([39]). Elevated 
CD4:CD8 ratios on BAL, a characteristic but not diagnostic finding in sarcoidosis, have also 
been documented in patients with CD ([40, 41]). 
α1 - antitrypsin deficiency: α1 - antitrypsin deficiency can lead to the development of 
pulmonary emphysema and hepatic dysfunction. In a study 10 patients, 7 with emphysema, 
who had concomitant α1- antitrypsin deficiency and IBD have identified. Combined with the 
complex effects of smoking on the prevalence and course of UC and CD, this observation 
has lead the authors to propose that, as in the lung, imbalances in neutrophil elastase 
regulation exhibited in α1-antitrypsin deficiency may enhance potential local tissue damage 
in the gastroenterological tract from smoking ([42]). 
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Intestinal manifestations of a pulmonary vasculitis such asWegener granulomatosis, Churg-
Strauss syndrome, microscopic polyangiitis, and pulmonary vasculitis have been reported. 
Bloody diarrhea, abdominal pain, and intestinal perforation have been described in these 
patients. The symptoms can mimic IBD and make diagnosis difficult without biopsy ([15]). 
Pulmonary infiltrates with eosinophilia (PIE syndrome); is a recognized complication of 
sulfasalazine, which is commonly used in the therapy of ulcerative colitis. There are also 
case reports of eosinophilic pneumonia in association with mesalamine therapy. However, 
this syndrome can occur in patients with inflammatory bowel disease who have no history of 
sulfasalazine use. Eosinophilia is frequently present in the peripheral blood, and chest 
radiographs often show peripheral infiltrates typical of chronic eosinophilic pneumonia ([2]). 
Necrobiotic nodules resemble radiographically the cavitating nodules that can be seen with 
either septic pulmonary emboli or Wegener's granulomatosis . Histologically, the nodules 
are composed of sterile aggregates of neutrophils with necrosis, findings that are similar to 
those of pyoderma gangrenosum, a cutaneous complication of inflammatory bowel disease 
([43]). 
Serositis: As a complication of inflammatory bowel disease, serositis involving intrathoracic 
structures has occurred in the form of pleural effusions, pericarditis, pleuropericarditis, and 
myopericarditis ([12]). The serosal fluid is exudative, with a cellular content generally 
composed primarily of neutrophils. In a single case in which pleural biopsy was reported, 
nonspecific inflammation without granulomas was found. The pericardium is uniquely 
involved in 45% of cases ([44]). 
Pulmonary embolism: Venous thromboembolism (VTE) represents a relevant cause of 
morbidity and mortality among patients with IBD. Compared to non-IBD subjects, patients 
with IBD are at a 3- to 4-fold increased risk of VTE and are affected by VTE at a younger age 
([45, 46, 47]). The majority of thromboembolic events among IBD patients are VTE, 
manifested as either deep venous thrombosis or pulmonary embolism, but arterial 
thromboembolism and venous thrombosis at unusual sites have also been reported ([48]). 
The pathogenesis of increased thrombotic risk among patients with IBD is unclear. The 
prevalence of inherited prothrombotic disorders is no higher among patients with IBD than 
in the general population. While laboratory markers of activation of the coagulation system 
have been found in some patients with IBD, the significance of this finding is unclear. IBD 
patients often have acquired thrombosis risk factors in conjunction with their disease or its 
treatment, including immobility, surgery, and central venous catheters. However, up to one 
third of thrombotic events among IBD patients occur while their disease is quiescent, 
suggesting ongoing thrombotic risk unrelated to disease activity or therapy ([49, 50, 51]). 
Active disease, fistulas, and abscesses are present in the majority of IBD patients at the time 
of the thromboembolic event. Furthermore, IBD patients are more often exposed to disease-
related risk factors that may provoke VTE, including surgery, immobilization, dehydration, 
and central venous catheters ([47, 48, 52]). Patients who present with the acute development 
of unexplained pulmonary symptoms, tachycardia, lower extremity swelling, and/or 
hypoxemia should be assessed for possible pulmonary embolism ([17]). 
Drug-induced Complications: Patients with inflammatory bowel disease are often treated 
with sulfasalazine and 5-aminosalicylic acid (5-ASA), both of which can cause pulmonary 
disease ([14, 53, 54]).  Methotrexate, infliximab, and azathioprine / 6-mercaptopurine are 
also used in selected patients, and can induce pulmonary toxicity. 
Sulfasalazine: Pneumonitis, commonly seen in conjunction with fever and rash, is a 
recognized complication of sulfasalazine therapy. Nearly one-half of affected patients 
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present with the clinical syndrome of pulmonary infiltrates with eosinophilia. The infiltrates 
are commonly in upper lobe (Figure 3) ([53]). 
 
 
 
 
Fig. 3. Chest radiograph and computed tomography of the patient showing bilaterally 
interstitial infiltrates with air-bronchogram in both lower lung fields ([53]) 
Other pulmonary disorders have also been associated with sulphasalazine, including 
interstitial lung disease, bronchiolitis obliterans with organizing pneumonia, granulomatous 
lung disease, and rarely pleural effusion ([12, 55]). 
Most reactions related to sulfasalazine or mesalamine are seen between 2-6 months of drug 
administration. The most common symptoms are dyspnea (76%), fever (68%), chest pain 
(65%) and cough (22%). Peripheral eosinophilia is found in almost half of the reported cases, 
diffusion capacity was decreased in a large percentage of patients and most had bilateral 
infiltrates or opacities on chest radiograph ([15]). A pulmonary picture consistent with 
Wegener's granulomatosis has also been attributed to sulfasalazine ([56]). 
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In general, patients with sulphasalazine-induced pulmonary disease improve with drug-
withdrawal; in one analysis, two of three patients who continued on the drug died ([52]). 
5-aminosalicylic acid: Pulmonary toxicity attributable to 5-aminosalicylic acid (5-ASA or 
mesalamine) is less common than with sulfasalazine. Some affected patients have diffuse or 
basilar infiltrates, sometimes with eosinophilia or may develop bronchiolitis obliterans ([53]). 
Methotrexate: Methotrexate is an analogue of the vitamin folic acid and inhibits cellular 
proliferation by inducing an acute intracellular deficiency of certain folate coenzymes. 
Serious toxicity may affect the lungs, liver, and bone marrow. Methotrexate can cause 
pneumonitis that can become life threatening. Symptoms typically include progressive 
shortness of breath, cough, and fever. Hypoxemia and tachypnea are always present, and 
chest radiograph often reveals a diffuse interstitial or mixed interstitial and alveolar 
infiltrate, commonly in the lower lung fields. Pulmonary function tests show a restrictive 
pattern with diffusion abnormalities ([15]). 
Azathioprine and 6-mercaptopurine: Immunomodulatory drugs, such as azathioprine 
(AZA) and 6-mercaptopurine (6-MP) can potentiate the therapeutic effect of glucocorticoids 
and exert a glucocorticoid-sparing effect in patients with glucocorticoid-dependent 
ulcerative colitis. Drug-induced hypersensitivity pneumonitis is a rare but potentially 
serious complication of therapy with these agents. Other pathologic patterns, such as usual 
interstitial pneumonia and bronchiolitis obliterans with organizing pneumonia, have rarely 
been reported in patients with inflammatory bowel disease treated with AZA or 6-MP ([57]). 
Infliximab: Infliximab, an inhibitor of tumor necrosis factor-alpha, is used in selected 
patients with Crohn's disease, particularly those with fistulizing disease. Infectious 
complications from use of infliximab are well-described, most notably in the development of 
tuberculosis ([58]). There are also case reports of interstitial pneumonitis developing in 
patients with rheumatoid arthritis and Crohn's disease treated with infliximab (Figure 4) ([59]). 
 
 
Fig. 4. High-resolution computed tomography of the thorax revealed extensive ground glass 
shadowing with right apical peribronchial consolidation ([59]) 
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7. Diagnosis and treatment 
The first step in determining appropriate therapy is to consider the possible role of drug-
induced disease and the possibility of superimposed bacterial infection. When patients 
with inflammatory bowel disease who are treated with sulfasalazine or 5-ASA develop 
pulmonary infiltrates with eosinophilia, it is reasonable to assume initially that drug-
induced disease is present and to discontinue the drug ([12]). The possible role of drug 
toxicity is less clear with other clinical presentations of parenchymal lung disease, such 
as interstitial disease or bronchiolitis obliterans with organizing pneumonia. In this 
setting, any decision concerning cessation of drug therapy should consider the relative 
severity of the pulmonary disease and the inflammatory bowel disease, which could flare 
if the drug is withdrawn. Possible superimposed bacterial or mycobacterial infection 
should be excluded in patients with fever, cough, or purulent sputum production. 
Appropriate antimicrobial therapy should be given if infection is found. Prophylaxis 
against venous thromboembolism (VTE) should be considered in hospitalized  
patients without evidence of gastrointestinal bleeding or other contraindications, since 
the risk of VTE may be increased in patients with inflammatory bowel disease ([47, 49, 
52,60, 61]). 
Antiinflammatory drugs: For those patients in whom neither drug therapy nor infection 
seems to be playing a role, inhaled or systemic glucocorticoids may be effective, depending 
upon the type of pulmonary complication. Inhaled glucocorticoid therapy, often in 
relatively high doses (eg, beclomethasone 1500-2000 mcg/day), is frequently effective in the 
various forms of airway inflammation. Large airway inflammation tends to be more 
responsive than bronchiolitis, presumably due to relatively poor delivery of the inhaled 
medication to the affected small airways. Patients with copious sputum production (greater 
than 50 mL/day) and those with bronchiectasis are also less likely to respond to inhaled 
glucocorticoids and may require oral glucocorticoids. Potentially life-threatening airway 
inflammation, as with subglottic involvement causing upper airway obstruction, may 
require intravenous glucocorticoids. The pulmonary parenchymal complications of 
inflammatory bowel disease require oral glucocorticoid therapy; we usually use prednisone 
at an initial dose of 0.5 to 1.0 mg/kg per day. Most patients have a good response to 
glucocorticoid therapy. The duration of treatment has not been well established, but is likely 
to be a number of months ([2]). 
Serositis in the form of pleural effusions may need therapy if the effusions produce 
symptoms. Nonsteroidal antiinflammatory therapy should be tried initially, but 
glucocorticoids may be necessary if the patient does not respond. A single case of cardiac 
tamponade requiring pericardial drainage has been reported ([17]). There is insufficient 
evidence to support the use of infliximab or other agents directed against tumor necrosis 
factor in the management of pulmonary disease associated with IBD. 
In conclusion, although most patients have subclinical disease, the pulmonologist must be 
aware of the multiple potential pulmonary manifestations that can occur in a patient with 
IBD. To get over this problem a complex work-up is needed ( Table 1. Based on Storch Et 
al. [15]). Otherwise, they tend to generate persistent and annoying symptoms, and can 
lead to destructive and irreversible changes in the airway wall, or the “end-stage lung” 
([12]). 
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Blood work 
  Complete blood count with differential 
  Comprehensive metabolic panel 
  Antineutrophil cytoplasmic antibodies 
  Angiotensin converting enzyme level 
  Erythrocyte sedimentation rate 
Radiographic 
  Chest x-ray 
  Computed tomography 
Other 
  Sputum culture/acid fast stain 
  Purified Protein Derivative 
  Kveim test 
Advanced 
  Pulmonary function testing 
  Bronchoscopy with alveolar lavage 
  Pulmonary biopsy 
  Lower extremity Doppler 
  Ventilation/perfusion scan 
  Computed tomography—angiogram 
  Hypercoagulability work-up 
Table 1. Work-up of pulmonary disease in IBD 
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